Latent Autoimmune Diabetes In Adults Pdf
Division of Human Genetics, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USADepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USACenter for Applied Genomics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 19104, USAInstitute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USADepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. Latent autoimmune diabetes in adults (LADA) is characterized by the presence of isletautoantibodies and initial insulin independence, which can lead to misdiagnosis oftype 2 diabetes (T2D). As such, understanding the genetic etiology of LADA could aidin more accurate diagnosis. However, there is ongoing debate regarding the exact definitionof LADA, so understanding its impact in different populations when contrasted withtype 1 diabetes (T1D) and T2D is one potential strategy to gain insight into its etiology.Unfortunately, the lack of consistent and thorough autoantibody screening around theworld has hampered well-powered genetic studies of LADA.
This review highlights recentgenetic and epidemiological studies of LADA in diverse populations as well as theimportance of autoantibody screening in facilitating future research.Keywords. Please enable JavaScript to view the Cell Press Commenting GuidelinesTo submit a comment for a journal article, please use the space above and note the following:. We will review submitted comments within 2 business days. This forum is intended for constructive dialog.
Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted. We recommend that commenters identify themselves with full names and affiliations. Comments must be in compliance with our. Comments will not be peer-reviewed.
Abstract:Latent Autoimmune Diabetes in Adults (LADA), although formally classified as Type 1Diabetes (T1D), very often (at least in Western countries) appear clinically with Type 2 Diabetes(T2D)-like features as overweight and insulin resistance. LADA patients do not need exogenous insulinat the time they are diagnosed with diabetes, but a large percentage will within a few years developneed for such treatment. The decline in beta cell function progresses much faster in LADA than inT2D, presumably because of the ongoing autoimmune assault in LADA, and therefore necessitates insulintherapy much earlier in LADA than in T2D. Despite high prevalence of LADA (about 10% of thetotal diabetic population in many countries), the treatment of LADA patients is far less elucidated thanis the case for T1D and T2D. Finding a treatment strategy for LADA from the time of diagnosis, thatcan reduce the decline of beta cell function, ensure adequate metabolic control and thereby reduce therisk of diabetic complications is thus an important clinical challenge.
Conclusions from the randomizedtreatment studies so far do not indicate an optimal treatment strategy in LADA. This review aimsto give an overview of current practices for the medical treatment of LADA as well as an update onresults from recent studies on the treatment of the disease.Keywords: LADA, GADA, treatment, randomized clinical trials, residual beta cell function, metabolic control. Title:Treatment of Latent Autoimmune Diabetes in Adults: What is Best?VOLUME: 15 ISSUE: 3Author(s):Ingrid K. Hals.Affiliation:Department of Endocrinology, St.
Latent Autoimmune Diabetes In Adults Ace
Olavs Hospital, Trondheim University Hospital, TrondheimKeywords:LADA, GADA, treatment, randomized clinical trials, residual beta cell function, metabolic control.Abstract:Latent Autoimmune Diabetes in Adults (LADA), although formally classified as Type 1Diabetes (T1D), very often (at least in Western countries) appear clinically with Type 2 Diabetes(T2D)-like features as overweight and insulin resistance. LADA patients do not need exogenous insulinat the time they are diagnosed with diabetes, but a large percentage will within a few years developneed for such treatment. The decline in beta cell function progresses much faster in LADA than inT2D, presumably because of the ongoing autoimmune assault in LADA, and therefore necessitates insulintherapy much earlier in LADA than in T2D. Despite high prevalence of LADA (about 10% of thetotal diabetic population in many countries), the treatment of LADA patients is far less elucidated thanis the case for T1D and T2D. Finding a treatment strategy for LADA from the time of diagnosis, thatcan reduce the decline of beta cell function, ensure adequate metabolic control and thereby reduce therisk of diabetic complications is thus an important clinical challenge. Conclusions from the randomizedtreatment studies so far do not indicate an optimal treatment strategy in LADA. This review aimsto give an overview of current practices for the medical treatment of LADA as well as an update onresults from recent studies on the treatment of the disease.